Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions
Aykut Çilli, Nesrin Öcal, Fatih Üzer, Funda Çoşkun, Can Sevinç, Ahmet Ursavaş, Pınar Yildiz, Pelin Pınar Deniz, Nilgün Yılmaz Demirci, Gamze Ozbey, Ahmet Yurttaş, Ismail Hanta
Topics & Concepts
MedicineDiscontinuationTolerabilityIdiopathic pulmonary fibrosisInternal medicineAdverse effectIncidence (geometry)PirfenidoneNintedanibNauseaPopulationLungPhysicsOpticsEnvironmental healthInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related DiseasesRheumatoid Arthritis Research and Therapies